BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1028 related articles for article (PubMed ID: 19015633)

  • 1. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
    Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
    Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
    Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
    Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
    Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
    Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
    Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
    Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
    Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
    Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
    Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
    Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells.
    Moon MS; Lee CJ; Um SJ; Park JS; Yang JM; Hwang ES
    Gynecol Oncol; 2001 Feb; 80(2):168-75. PubMed ID: 11161855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].
    Bian J; Yu X; Dong J; Zhao W; Zhou Y; Luan Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):271-3. PubMed ID: 15617346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
    Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
    Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
    Yamato K; Yamada T; Kizaki M; Ui-Tei K; Natori Y; Fujino M; Nishihara T; Ikeda Y; Nasu Y; Saigo K; Yoshinouchi M
    Cancer Gene Ther; 2008 Mar; 15(3):140-53. PubMed ID: 18157144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
    López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
    Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
    Koivusalo R; Krausz E; Helenius H; Hietanen S
    Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy.
    Liu Y; Heilman SA; Illanes D; Sluder G; Chen JJ
    Cancer Res; 2007 Mar; 67(6):2603-10. PubMed ID: 17363579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
    Rampias T; Sasaki C; Weinberger P; Psyrri A
    J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of TP53 in Cervical carcinogenesis.
    Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
    Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
    García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
    Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines.
    Liang XH; Volkmann M; Klein R; Herman B; Lockett SJ
    Oncogene; 1993 Oct; 8(10):2645-52. PubMed ID: 8397367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells.
    Bañuelos A; Reyes E; Ocadiz R; Alvarez E; Moreno M; Monroy A; Gariglio P
    J Pharmacol Exp Ther; 2003 Aug; 306(2):671-80. PubMed ID: 12750435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells.
    Jeong Seo E; Jung Kim H; Jae Lee C; Tae Kang H; Seong Hwang E
    Gynecol Oncol; 2004 Jul; 94(1):40-7. PubMed ID: 15262117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells.
    Rincon-Orozco B; Halec G; Rosenberger S; Muschik D; Nindl I; Bachmann A; Ritter TM; Dondog B; Ly R; Bosch FX; Zawatzky R; Rösl F
    Cancer Res; 2009 Nov; 69(22):8718-25. PubMed ID: 19887612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.